Eupraxia Pharmaceuticals Inc. (EPRX)

NASDAQ: EPRX · USD

$7.37

+0.29 (+4.1%)· Recorded snapshot

Market cap	487.5M
Net income (ttm)	-52.7M
EPS (ttm)	-$1.01
Shares out	65.9M
Volume	399,979
Beta	1.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -52.7M
EPS (ttm): -$1.01
Market cap: 487.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-66.7

P25 n/aP50 n/aP75 n/a

ROIC-46.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EPRX indicators

Market & fundamental data

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001581178
Company name	Eupraxia Pharmaceuticals Inc.
Country	Canada
Country code	US
CUSIP number	29842P105
Earnings date	2026-11-10
Earnings time	amc
Employees	49
Employees change	16
Employees growth	48.48%
Enterprise value	$382.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2011
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	CA29842P1053
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$487.5M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	No
Price	$7.37
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	EPRX
Website	https://www.eupraxiapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-13.71%
FCF / EV yield	-10.52%
FCF yield	-8.16%
P/B ratio	3.61x
Price / tangible book value	4.6x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.1M
ROA	-43.66%
ROA (5Y)	-61.98%
ROCE	-43.47%
ROE	-66.7%
ROIC	-46.8%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-753,723
Depreciation and amortization	$239,363
EBIT	$-57.1M
EBITDA	$-56.9M
EPS	$-1.01
FCF per share	$-0.58
Financing cash flow	$151.4M
Free cash flow	$-38.2M
Free cash flow minus SBC	$-49.7M
Income taxes	$55,002
Investing cash flow	$-80.5M
Net cash flow	$32.7M
Net income	$-52.7M
Operating cash flow minus SBC	$-48.9M
Operating income	$-57.1M
Stock-based compensation	$11.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$1.55
Debt / equity	0.01
Long-term assets	$3.1M
Long-term liabilities	$1.7M
Net cash (debt)	$131.8M
Net cash / market cap	28.15%
Net cash growth	568.09%
Net debt / equity	-1.02
Piotroski F-Score	2
Property, plant and equipment	$3M
Shareholders' equity	$129.7M
Tangible book value	$101.8M
Tangible book value per share	$1.55
Total assets	$139.9M
Total cash	$133.7M
Total debt	$1.8M
Total liabilities	$10.2M
WACC	10.89%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$136.8M
Current liabilities	$8.6M
Current ratio	16
Net working capital	$-5.2M
Quick ratio	15.71
Working capital	$128.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-47.8%
Dividend yield	0%
Shareholder yield	-47.8%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.04
1D price change	4.1%
1M price change	-9.74%
1M total return	-9.74%
1W price change	-4.74%
1W total return	-4.74%
1Y price change	30.74%
1Y return CAGR	30.77%
1Y total return	30.74%
20-day SMA	$7.26
200-day SMA	$7.32
3M price change	17.18%
3M total return	17.18%
3Y price change	82.67%
3Y return CAGR	22.24%
3Y total return	82.66%
50-day SMA	$7.58
50-day SMA vs 200-day SMA	50over200
52-week high	$9.32
52-week high date	2026-01-21
52-week low	$5.25
52-week low date	2025-11-06
5Y price change	221.33%
5Y return CAGR	26.3%
5Y total return	221.33%
6M price change	0.28%
6M total return	0.28%
All-time high	$9.32
All-time high date	2026-01-21
All-time low	$0.85
All-time low date	2022-06-27
Average true range (ATR)	$0.50
Average volume	911K
Beta (5Y)	1.22
Change from 52-week high	-20.92%
Change from 52-week low	40.38%
Change from all-time high	-22.42%
Change from all-time low	750.49%
Change from open	3.95%
Day's gap	0.14%
Dollar volume	$2.9M
High price	$7.39
Low price	$7.08
Monthly RSI	56.37
Open price	$7.09
Position in 52-week range	93.55%
Premarket change	1.55%
Premarket close	$7.08
Premarket price	$7.19
Previous close	$7.08
Price vs 150-day SMA	2.76%
Price vs 20-day SMA	-0.44%
Price vs 200-day SMA	-1.24%
Price vs 50-day SMA	-4.67%
Relative volume	0.44
RSI	48.03
Sharpe ratio	0.67
Sortino ratio	1.18
Volume	400K
Weekly RSI	50.82
YTD price change	-4.24%
YTD total return	-4.24%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.7M
Float percentage	84.47%
Shares change (QoQ)	16.77%
Shares change (YoY)	47.8%
Shares held by insiders	15.53%
Shares held by institutions	43.7%
Shares outstanding	65.9M
Short % of float	12.21%
Short % of shares	10.32%
Short ratio	10.7 days

Deeper analysis on EPRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EPRX report

Is a complete EPRX research report available?

No complete published report is available for Eupraxia Pharmaceuticals Inc. (EPRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Eupraxia Pharmaceuticals Inc. (EPRX)

Price

Financial snapshot

Fair-value bridge

Latest news · EPRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EPRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EPRX

Frequently asked questions